Evidence map›Paper›PMID 37226235›Full record

ArticleBMC cancer2023

Circulating tumor cells (CTCs) and hTERT gene expression in CTCs for radiotherapy effect with lung cancer.

Ying Xu, Xue Ren, Tong Jiang, Shuang Lv, Kuanke Gao, Yunen Liu, Ying Yan

Abstract read
In one paragraph

Article in BMC cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Liquid biopsy techniques and lung cancer: diagnosis, monitoring and evaluation.Journal of experimental & clinical cancer research : CR · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ying Xu *Department of Radiation Oncology, General Hospital of Northern Theater Command, No. 83 Wenhua Road, Shenhe District, Shenyang, l10016, China.
Xue Ren *Department of Radiation Oncology, General Hospital of Northern Theater Command, No. 83 Wenhua Road, Shenhe District, Shenyang, l10016, China.
Tong JiangDepartment of Radiation Oncology, General Hospital of Northern Theater Command, No. 83 Wenhua Road, Shenhe District, Shenyang, l10016, China.
Shuang LvShandong Province Heze Municipal Hospital, Heze, 274000, China.
Kuanke GaoDepartment of Radiation Oncology, General Hospital of Northern Theater Command, No. 83 Wenhua Road, Shenhe District, Shenyang, l10016, China.
Yunen LiuShenyang Medical College, No. 146 Road, Huanghe South Street, Huanggu District, Shenyang, 110034, China. lye9901@163.com.
Ying YanDepartment of Radiation Oncology, General Hospital of Northern Theater Command, No. 83 Wenhua Road, Shenhe District, Shenyang, l10016, China. yanyingdoctor@sina.com.

Funding

Fund program Major Science and Technology Project of Liaoning Province 2019JH/10300007
6 · The paper itself

Abstract

backgroundCirculating tumor cells (CTCs) are important biological indicators of the lung cancer prognosis, and CTC counting and typing may provide helpful biological information for the diagnosis and treatment of lung cancer.

methodsThe CTC count in blood before and after radiotherapy was detected by the CanPatrol™ CTC analysis system, and the CTC subtypes and the expression of hTERT before and after radiotherapy were detected by multiple in situ hybridization. The CTC count was calculated as the number of cells per 5 mL of blood.

resultsThe CTC positivity rate in patients with tumors before radiotherapy was 98.44%. Epithelial-mesenchymal CTCs (EMCTCs) were more common in patients with lung adenocarcinoma and squamous carcinoma than in patients with small cell lung cancer (P = 0.027). The total CTCs (TCTCs), EMCTCs, and mesenchymal CTCs (MCTCs) counts were significantly higher in patients with TNM stage III and IV tumors (P < 0.001, P = 0.005, and P < 0.001, respectively). The TCTCs and MCTCs counts were significantly higher in patients with an ECOG score of > 1 (P = 0.022 and P = 0.024, respectively). The TCTCs and EMCTCs counts before and after radiotherapy affected the overall response rate (ORR) (P < 0.05). TCTCs and ECTCs with positive hTERT expression were associated with the ORR of radiotherapy (P = 0.002 and P = 0.038, respectively), as were TCTCs with high hTERT expression (P = 0.012). ECOG score (P = 0.006) and post-radiation TCTCs count (P = 0.011) were independent factors for progression-free survival (PFS) and TNM stage (P = 0.054) and pre-radiation EMCTCs count (P = 0.009) were independent factors of overall survival (OS).

conclusionThis study showed a high rate of positive CTC detection in patients with lung cancer, and the number, subtype, and hTERT-positive expression of CTCs were closely related to patients' ORR, PFS, and OS with radiotherapy. EMCTCs, hTERT-positive expression of CTCs are expected to be important biological indicators for predicting radiotherapy efficacy and the prognosis in patients with lung cancer. These results may be useful in improving disease stratification for future clinical trials and may help in clinical decision-making.

Indexed as

Adenocarcinoma of LungLung NeoplasmsNeoplastic Cells, CirculatingSmall Cell Lung CarcinomaGene ExpressionHumansCirculating tumor cellsEfficacyhTERTLung cancerRadiotherapy

Identifiers

PMID37226235
PMCPMC10207832

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.